CSIMarket
 
Pepgen Inc   (PEPG)
Other Ticker:  
 
 
Price: $13.6500 $-1.79 -11.593%
Day's High: $15.82 Week Perf: -1.73 %
Day's Low: $ 13.61 30 Day Perf: -3.26 %
Volume (M): 96 52 Wk High: $ 20.00
Volume (M$): $ 1,309 52 Wk Avg: $9.19
Open: $15.81 52 Wk Low: $3.72



 Market Capitalization (Millions $) 325
 Shares Outstanding (Millions) 24
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -74
 Cash Flow (TTM) (Millions $) -3
 Capital Exp. (TTM) (Millions $) 6

Pepgen Inc
A clinical-stage biotechnology company is advancing the next generation of oligonucleotide therapeutics to treat severe neuromuscular and neurologic diseases. The Enhanced Delivery Oligonucleotide (EDO) platform is the foundation of their research and development, which leverages cell-penetrating peptides to enhance the uptake and activity of conjugated oligonucleotide therapeutics. The company has in-licensed an extensive patent portfolio from the University of Oxford and the Medical Research Council of United Kingdom Research and Innovation to support the further advancement and potential commercialization of their EDO platform. EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and they have observed their ability to transport oligonucleotides into a broad range of target tissues. They are generating a pipeline of oligonucleotide therapeutic candidates that target the root cause of serious diseases, and their lead product candidate, PGN-EDO51, is currently in clinical-stage development. The company has completed a first-in-human Phase 1 clinical trial in healthy volunteers, with the goal of treating individuals with Duchenne muscular dystrophy. The results of the trial showed that PGN-EDO51 had the highest levels of exon skipping and oligonucleotide delivery in humans following a single dose when compared to publicly available data for other approaches. The company is planning two, parallel Phase 2 studies of PGN-EDO51 in DMD patients whose disease is amenable to an exon 51 skipping approach, one of which is expected to be an open-label, multiple ascending dose study in Canada in the first half of 2023. The company is also developing PGN-EDODM1 for the treatment of myotonic dystrophy, myotonic dystrophy pathogenesis. Preclinical studies have demonstrated a favorable safety profile and strong pharmacological activity in relevant DM1 disease models. We plan to initiate a first-in-human Phase 1 clinical trial for PGN-EDODM1 in the second half of 2023, pending clearance by the FDA of an IND filing and/or clearance by the European Medicines Agency of a CTA, in each case, anticipated in the second half of this year. Our clinical development program for PGN-EDODM1 is intended to establish proof-of-concept and a preliminary safety profile for this novel therapeutic candidate, with the ultimate goal of transforming the treatment of DM1. In addition to our lead programs, we have a pipeline of additional EDO-based oligonucleotide therapeutics in preclinical development for the treatment of other severe neuromuscular and neurologic diseases, including spinal muscular atrophy and amyotrophic lateral sclerosis. We believe that our EDO platform has the potential to address significant unmet medical needs in these disease areas and beyond, and we are committed to advancing our platform and therapeutic candidates through rigorous scientific investigation and clinical development. Our team is composed of experienced drug developers, scientists, and industry veterans who share a common vision of improving the lives of patients affected by severe neuromuscular and neurologic diseases through the development of transformative therapies.


   Company Address: 321 Harrison Ave. 8th Floor Boston 2118 MA
   Company Phone Number: 797-0979   Stock Exchange / Ticker: NASDAQ PEPG
   PEPG is expected to report next financial results on March 22, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Transforming the Treatment Landscape for Duchenne Muscular Dystrophy: PepGen's PGN-EDO51 Shows Promise in Phase 2 Clinical Trial

Published Mon, Mar 4 2024 12:00 PM UTC

Duchenne muscular dystrophy (DMD) is a devastating and progressive genetic disorder that primarily affects young boys, leading to muscle weakness, loss of ambulation, and potentially life-threatening complications. Despite decades of research, there is still an unmet medical need for effective treatments that can halt or slow down the progression of this debilitating disease...

Shares

PepGen Inc. Makes Waves with $80.1 Million Underwritten Offering of Common Stock

Published Wed, Feb 7 2024 12:30 PM UTC

PepGen Inc. Announces Pricing of $80.1 Million Underwritten Offering of Common Stock
BOSTON, Feb. 07, 2024 ?? PepGen Inc. (Nasdaq: PEPG) made a significant announcement today regarding the pricing of an underwritten offering of 7,530,000 shares of its common stock at a price of $10.635 per share. The aggregate gross proceeds to PepGen from this offering are expected to b...

Product Service News

PepGen's PGN-EDO51: Unleashing Hope for Duchenne Muscular Dystrophy with Exon Skipping

Published Mon, Jan 8 2024 12:01 PM UTC

As the race to find effective treatments for Duchenne Muscular Dystrophy (DMD) continues, PepGen has recently made a significant announcement that has captured the attention of medical experts and investors alike. The company has confirmed that the first patient has been dosed in the CONNECT1-EDO51 Phase 2 clinical trial of their groundbreaking drug, PGN-EDO51, targeting DMD...

Clinical Study

PepGen Advances to Clinical Trials as it Tests PGN-EDODM1 Against Myotonic Dystrophy Type 1

Published Mon, Dec 18 2023 1:01 PM UTC


Biopharmaceutical company, PepGen, has announced the first successful administration of their novel drug candidate, PGN-EDODM1 to a patient. This marks the initiation of a Phase 1 clinical trial named FREEDOM-DM1, aimed at combating Myotonic Dystrophy Type 1 (DM1), a frequently occurring form of muscular dystrophy.
PGN-EDODM1 has been engineered to provide a new so...

Pepgen Inc

PEPG Sets the Stage on Fire with Record-Breaking Performance in Q3 of 2023!



The recent financial results of several companies within the Major Pharmaceutical Preparations industry have showcased the current state of affairs within the sector. Among these is Pepgen Inc, an emerging growth company that has reported significant operating shortfalls. This article will delve into the facts and interpret the implications of Pepgen Inc's financial performance for the industry as a whole.
Financial Results of Pepgen Inc:
Pepgen Inc recently disclosed an operating shortfall of $-24.78 million for the third quarter of 2023. This figure represents a deterioration from the $-19.554 million shortfall reported in the third quarter of 2022. Similarly, the company reported a year-on-year increase in its operating shortfall from $-18.607 million in the same time period, indicating a concerning trend.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com